Miscarriage patients have fewer treatment options in states with abortion bans, study shows

Pregnant patients dealing with miscarriages in states with abortion bans face limited healthcare management options, as revealed by a recent study in the Journal of the American Medical Association. The research highlights a notable shift away from the two-drug approach involving mifepristone, which is crucial for managing miscarriages. This situation underscores the broader implications for reproductive healthcare access and the potential negative impact on patient outcomes in regions where abortion is heavily restricted.